Median systemic therapy–free survival split along ctDNA status in a Phase 2 oligometastatic clear-cell RCC study: patients with ctDNA-positive by a tumor‑informed assay moved to systemic treatment in a median of 27 months, versus 54 months for ctDNA‑negative patients maintained on metastasis‑directed radiotherapy without systemic therapy. Among ctDNA‑negative patients kept on local treatment, overall survival was 94% at two years and 87% at three years. Notably, 94% of patients tested at baseline had ctDNA levels below 100 ppm, underscoring the low tumor fraction characteristic of RCC and the need for ultrasensitive detection.
The core development is a Lancet Oncology publication reporting an investigator‑initiated, single‑arm trial (NCT03575611) evaluating sequential metastasis‑directed therapy without systemic agents in oligometastatic clear‑cell RCC, with circulating tumor DNA assessed as an exploratory biomarker using Myriad Genetics’ tumor‑informed, whole‑genome MRD assay (Precise MRD). The study links assay positivity with an earlier transition to systemic treatment. It suggests that ctDNA-negative patients can be maintained on local therapy for an extended period without an apparent survival penalty compared to current follow-up. While not designed to demonstrate causality, the dataset provides one of the more mature looks at MRD performance in a notoriously low‑shedding tumor type.
Strategically, the publication signals a push to extend MRD utility beyond colorectal and other higher‑shedding cancers into RCC, where prior assays have struggled with sensitivity. Myriad is positioning a whole‑genome, variant‑dense approach to quantify very low ctDNA levels and convert MRD from a prognostic signal into a decision tool for de‑escalation. The timing aligns with payer demands for clinical utility and the growing interest of guideline bodies in biomarker-guided treatment reduction, as well as intensifying competition among MRD platforms. The choice to anchor the case in a de‑escalation setting is deliberate: demonstrating that molecularly selected patients can avoid or delay IO/TKI regimens without compromising outcomes is a more straightforward path to health‑economic value than marginal improvements layered onto systemic therapy.
For sponsors, the signal opens a design lever in oligometastatic RCC: enrich or stratify by ctDNA status to power trials on systemic therapy–free survival or time to next systemic therapy, potentially shrinking sample sizes and clarifying treatment algorithms around metastasis‑directed radiotherapy. Sites should anticipate operational implications of tumor‑informed workflows—archival tissue retrieval, assay build time, and coordinated phlebotomy around radiation schedules—along with the need for tight pre‑analytic control when quantifying sub‑100‑ppm ctDNA. CROs and lab vendors will see increased demand for harmonized processes and rapid turnaround to keep local therapy pathways on schedule. Regulators and payers will focus on whether ctDNA‑guided de‑escalation is prospectively validated and reproducible across platforms, and whether predefined decision thresholds translate into consistent, patient‑level benefit.
The next test is prospective, randomized evidence where ctDNA directly governs the decision to defer or start systemic therapy, with endpoints that matter to regulators and payers: durability, quality of life, and resource utilization. Key risks include confounding in single-arm datasets, variability in ctDNA detectability across lesion burden and sites of metastasis, and generalizability beyond clear-cell histology. Analytical reproducibility at very low tumor fractions, lead‑time advantage over imaging, turnaround time from tissue acquisition to first result, and alignment with evolving oversight of lab‑developed tests will also shape adoption. Watch for MRD‑guided oligometastatic RCC trials that pre‑specify action thresholds, external validation cohorts, and health‑economic analyses quantifying avoided systemic therapy. Evidence that the assay can reliably move MRD from prognostic to actionable in RCC will determine whether this publication marks a niche signal or the start of a broader shift in how oligometastatic disease is managed.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
